Physician profile
Kenneth L Schaecher
NPI 1245262492
$333,328.59
in general payments reported to CMS, 2019-2025
56 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $20K · 2021: $33K · 2022: $53K · 2023: $57K · 2024: $43K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $119K · Travel and Lodging: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $6,714 · Honoraria: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $118,569.00 |
| Travel and Lodging | $24,842.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,182.04 |
| Food and Beverage | $6,714.28 |
| Honoraria | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $153,343.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,289.67 | 2019-2025 | Jardiance |
| Eli Lilly and Company | $15,600.00 | 2020-2025 | Kisunla |
| Pacira Pharmaceuticals Incorporated | $9,547.97 | 2024-2025 | Exparel, Zilretta, Iovera |
| Astrazeneca Uk Limited | $9,155.71 | 2019 | |
| Lilly USA, LLC | $8,800.00 | 2024-2025 | Kisunla, Taltz |
| Biomarin Pharmaceutical INC. | $8,473.94 | 2023-2024 | Voxzogo 1.2mg |
| Celgene Corporation | $7,812.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $7,784.14 | 2019 | |
| Argenx US, INC. | $7,429.05 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Ferring Pharmaceuticals INC. | $7,351.06 | 2025 | Adstiladrin |
| Janssen Global Services, LLC | $7,170.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,177.04 | 2025 | Caplyta |
| Genmab U.S., INC. | $5,610.74 | 2023 | Epkinly |
| Pfizer INC. | $5,081.04 | 2019-2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Schaecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.